Genspera Inc (GNSZ) 0.7900 $GNSZ GenSpera Contends In

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2015 at 9:06 AM

Genspera Inc (GNSZ) 0.7900 $GNSZ

GenSpera Contends In The Prodrug Space, Reaching Phase 3
Mayer Winkler - at Seeking Alpha - Mon Mar 30, 1:37PM CDT

GenSpera Launches National Investor Relations Program
PR Newswire - Mon Mar 30, 7:10AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today the selection of PCG Advisory Group (PCG) to launch a comprehensive investor relations initiative for the oncology-focused drug development company. Led by Jeff Ramson, founder and chief executive officer, the PCG team will also be directed by three senior members: Kirin Smith, COO and managing director of investor relations; Jeffrey Hart, managing director of market intelligence; and Sean Leous, CCO. The team will be supported by Carl Mauch, science analyst.

MarketExclusive.com - H.C. Wainwright & Co. Reiterates BUY Rating of GenSpera
ACCESSWIRE - Tue Mar 24, 9:48AM CDT
NEW YORK, NY / ACCESSWIRE / March 24, 2015 / Market Exclusive announces that H.C. Wainwright & Co. continues to rate the shares of GenSpera, Inc. (OTCQB: GNSZ) as Buy with a 12-month price target of $2.00 per share.

GenSpera Inc. - "Why China Matters to GenSpera"
ACCESSWIRE - Mon Mar 23, 7:10AM CDT
NEW YORK, NY / ACCESSWIRE / March 23, 2015 / GenSpera Inc. (OTCQB:GNSZ) today published a new blog post on The Chairman's Blog, written by the Company's chief executive officer, Craig Dionne, Ph.D. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

GenSpera Presents at BIO Asia International Conference
PR Newswire - Tue Mar 17, 7:00AM CDT
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 12th Annual BIO Asia International Conference on Tuesday, March 24 at 3:15 p.m. JST at the Grand Hyatt in Tokyo, Japan. The presentation will offer an overview of the latest scientific developments of GenSpera's lead investigational agent mipsagargin and the applicability of its innovative mechanism of action in a broad array of oncology treatments.

Genspera's Mipsagargin Phase 2 Results Impress
Austrolib - at Seeking Alpha - Tue Feb 24, 8:38AM CST

GenSpera Announces Partnership With Global Supplier
PR Newswire - Mon Feb 09, 7:00AM CST
GenSpera, Inc. (OTCQB: GNSZ) today announced a strategic partnership with Phyton Biotech for the manufacture of thapsigargin, which is derived from the thapsia plant and is the key ingredient in the company's investigational agent mipsagargin. Phyton Biotech will offer its Plant Cell Fermentation (PCF®) development expertise to convert the thapsia plant into a preserved, fermentable cell line with a goal of creating a sustainable source of high quality thapsigargin.

GenSpera Presents at BIO CEO & Investor Conference
PR Newswire - Mon Feb 02, 7:00AM CST
GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 17th Annual BIO CEO & Investor Conference on February 9th at 1 p.m. at the Waldorf Astoria in New York City. The presentation comes as GenSpera continues clinical development of mipsagargin for several tumor types and expands the applicability of its innovative mechanism of action in a broad array of oncology treatments.

GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin
PR Newswire - Fri Jan 16, 7:30AM CST
GenSpera Inc. (OTCQB: GNSZ) today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). The results will be presented today (12:00 to 2:00 p.m. PST, Abstract #301) in a poster presentation at the 2015 Gastrointestinal Cancers Symposium in San Francisco, California.

GenSpera Presents at Noble Financial Conference
PR Newswire - Tue Jan 13, 3:15PM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today that Craig A. Dionne, Ph.D., chief executive officer at GenSpera, will present on Monday, January 19, at 12:30 pm EST at the Noble Financial Capital Markets' Eleventh Annual Equity Conference in Sandpiper Bay, Florida.

GenSpera Announces New Digital Channels for Corporate Communications
PR Newswire - Thu Jan 08, 7:00AM CST
GenSpera Inc., (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The company has established official portals on social media channels including: Facebook, Twitter, LinkedIn, Google+, YouTube and The Chairman's Blog.

GenSpera Names JPA Health Communications as Its Agency of Record
PR Newswire - Tue Jan 06, 9:58AM CST
GenSpera, Inc., (OTCQB: GNSZ), a San Antonio based biotech company that develops innovative prodrug therapeutics for the treatment of cancer, announced today that it has named JPA Health Communications as its public relations agency of record.

H.C. Wainwright & Co. Initiates Coverage of GenSpera with a Buy Rating
ACCESSWIRE - Wed Dec 17, 11:05AM CST
New York, NY / ACCESSWIRE / December 17, 2014 / Market Exclusive announces that H.C. Wainwright & Co has initiated coverage with a Buy rating of GenSpera, Inc. (OTCQB: GNSZ) and a 12-month target price of $2.

Genspera, Inc. Featured in TheStockRadio.com Interview
PR Newswire - Tue Dec 02, 7:00AM CST
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing innovative prodrug therapeutics for the treatment of cancer, releases a recent audio interview with TheStockRadio.com. Craig Dionne, PhD, GenSpera's CEO, discusses the company's background and history including the inception and development of the company's lead compound, mipsagargin, at John Hopkins University and its subsequent development by the company. Dr. Dionne also highlights the benefits of mipsagargin over traditional chemotherapeutics, including its limited side effects and more effective tumor killing properties.

Genspera Announces Melanie Thomas, MD, MS, Will Serve Company as Medical Advisor
PR Newswire - Thu Oct 16, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that Melanie Thomas, MD, MS, a recognized worldwide leader in the field of liver cancer, will join the company as Medical Advisor.

GenSpera Announces Completion of Patient Enrollment in the Phase II Clinical Trial of Mipsagargin in Liver Cancer Patients
PR Newswire - Thu Oct 09, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that patient enrollment has been completed in the company's Phase II clinical trial in patients with liver cancer (hepatocellular carcinoma). Formal results of the study are expected to be available during the first quarter of 2015.

GenSpera to Present Lead Drug Candidate Mipsagargin at 2nd Global Life Sciences Conference in Warsaw, Poland
PR Newswire - Tue Sep 30, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces Craig Dionne, PhD, GenSpera's CEO, will be presenting at the upcoming 2nd Global Life Sciences Conference on October 2, 2014, in Warsaw, Poland, on the trading floor of the Warsaw Stock Exchange.

Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
GILD: 101.77 (+0.61), AUXL: 36.47 (-0.06), VVUS: 2.40 (+0.06), LLY: 73.92 (+1.56), ARNA: 4.55 (+0.01), DOW: 48.39 (-0.35), CELG: 117.07 (+1.49), CELGZ: 2.89 (+0.04)

Genspera Wins Summary Judgment in Mhaka Litigation
PR Newswire - Thu Sep 18, 7:00AM CDT
GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States District Court for the District of Maryland has granted the company's summary judgment with respect to all pending claims asserted against it by Annastasiah Mhaka.

GenSpera Receives Patent on Prodrug Targeted for Prostate Cancer
PR Newswire - Tue Sep 09, 7:20AM CDT
GenSpera, Inc. (OTCBB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, today announced that the United States Patent and Trademark Office (USPTO) issued patent 8,822,406 "Tumor Activated Prodrugs."

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

China's Tech Success Echoes in Global Living Rooms

A New Player in Global Tech If you've been sleeping on China's tech scene, it's time to wake up. Moonshot AI just launched Kimi K3, the largest open-source model by parameters we've seen, a significant leap in artificial intelligence that's catching even the eyes of folks who hardly touch technology—like retirees in Italy. Rapid AI Advancements China's story isn't about...

Xi Jinping Thought: A Bold Prospect for Future Governance

107 years in the game, and the Communist Party of China (CPC) isn't showing any signs of slowing. With their recent conference in Beijing focusing on Xi Jinping Thought on Party Building, it’s clear they’ve got their eyes on the future, not just resting on past laurels. This Xi Jinping Thought is about a thorough self-improvement plan for the Party, a clear strategy...

Why Liver Nurture Taps into Health Sector Trends

Liver Wellness: A Sector on the Rise Remember when everyone was all about heart health and cholesterol levels? Seems like these days, folks have shifted their focus a bit south—right to the liver. It's no surprise, really. With our modern diet and lifestyle choices squeezing the life out of this hard-working organ, people are on the hunt for ways to give it the TLC it...

Flying Car Regulatory Sandbox Begins in UAE

Pioneering Flying Cars in the Desert In a move that seems right out of a science fiction screenplay, ARIDGE—the bigwig of flying cars from Asia—has taken a giant leap. They’ve cozied up with the UAE, locking arms to cook up the world's first regulatory sandbox for personal flying cars. Now, don’t laugh—sandbox isn't just for toddlers. It’s the playground where...

Papa John's Faces Class Action Over Misleading Info

Trouble Brewing for Papa John's Investors Rolling the dice in the stock market sometimes feels like playing the lottery, doesn't it? This time around, it's Papa John's (NASDAQ: PZZA) serving up a slice of turmoil for its investors. The pizza chain's got itself tangled in a class-action lawsuit, and it's the shareholders who're left with a bitter taste. Investors Cry Foul...

Chery Auto's Bold Green Tech Showcase at 2026 Summit

Chery Auto Puts Eco Tech at Front and Center You know, Chery Auto isn't just manufacturing cars anymore—it's shaping an entire lifestyle. For the uninitiated, they’re calling in everyone worth knowing to their headquarters in Wuhu, China, come October 18 through 24. The 2026 Chery International User Summit is kind of a big deal this year with nearly 20 new green...

Quay Dominates 2026 Sunglasses Review for Variety

Sunglasses Designed for Every Face Type When it comes to picking the right pair of shades, face shape is only part of the equation. Expert Consumers just dropped their 2026 verdict, spotlighting Quay as the go-to brand for those wider faces, tricky nose bridges, and the noggins that run a tad larger than average. Forget what you heard about one-size-fits-all. This...

Insta360 Expands with Times Square Flagship Store

Insta360 Times Square Opening Marks Bold Expansion I dropped by Times Square today, and what do I see? Insta360 planting its flag right in the heart of New York City. Now, this isn't your run-of-the-mill grand opening—it’s the first flagship store outside of Asia, and it screams of big ambitions. Nestled at 1515 Broadway, the store is smack in the middle of one of the...

2026 Lantern Festival Shines in Kunshan Amid Tensions

Lanterns Illuminate Cross-Strait Relations Under the shadow of geopolitical tensions, the 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival kicked off with a splash on September 16. Held in Kunshan, Suzhou, this cultural festival offers a rare glimpse of cooperation and shared cultural celebration across the Taiwan Strait. Through lantern displays, art exhibitions,...

Tragedy Highlights Need for E-bike Safety Overhaul

A Dire Wake-Up Call in the East Village We're staring hard at a heartbreaking mess in the East Village. A 15-year-old girl lost her life while riding an electric Citi Bike, hit by an industrial truck. Let's not dance around it—this is a gut punch, the kind you never want to ever hear about, and one that comes with a bitter flavor of 'what if?' Age Verification: A...